@article{37a5da938a5949f9a1fce1703de804c5,
title = "2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee",
author = "Virani, \{Salim S.\} and Morris, \{Pamela B.\} and Anandita Agarwala and Ballantyne, \{Christie M.\} and Birtcher, \{Kim K.\} and Kris-Etherton, \{Penny M.\} and Ladden-Stirling, \{Amanda B.\} and Michael Miller and Orringer, \{Carl E.\} and Stone, \{Neil J.\}",
note = "Funding Information: This ECDP aims to provide the risks and benefits of these approaches based on the best available evidence at the time of its publication. Ongoing randomized clinical trials of EPA only in patients with coronary artery disease (119) and selective peroxisome proliferator-activated receptor alpha agonists in patients with type 2 diabetes mellitus (18) will inform future iterations of guidelines as well as ECDPs. Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121). Pending outcomes trials, studies targeting specific proteins in these novel pathways also have the potential to provide clinicians with multiple options to address triglyceride-based ASCVD risk in patients treated with maximally tolerated statin therapy.",
year = "2021",
month = aug,
day = "31",
doi = "10.1016/j.jacc.2021.06.011",
language = "English (US)",
volume = "78",
pages = "960--993",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier Inc.",
number = "9",
}